SAREPTA THERAPEUTICS INC (1SRPT.MI) Fundamental Analysis & Valuation

BIT:1SRPT • US8036071004

Current stock price

14.74 EUR
-4.1 (-21.76%)
Last:

This 1SRPT.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. 1SRPT.MI Profitability Analysis

1.1 Basic Checks

  • 1SRPT had negative earnings in the past year.
  • 1SRPT had a negative operating cash flow in the past year.
  • In the past 5 years 1SRPT reported 4 times negative net income.
  • 1SRPT had a negative operating cash flow in each of the past 5 years.
1SRPT.MI Yearly Net Income VS EBIT VS OCF VS FCF1SRPT.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M -400M -600M

1.2 Ratios

  • 1SRPT has a Return On Assets (-21.30%) which is comparable to the rest of the industry.
  • With a Return On Equity value of -62.55%, 1SRPT perfoms like the industry average, outperforming 58.02% of the companies in the same industry.
Industry RankSector Rank
ROA -21.3%
ROE -62.55%
ROIC N/A
ROA(3y)-10.59%
ROA(5y)-13.51%
ROE(3y)-36.51%
ROE(5y)-67.48%
ROIC(3y)N/A
ROIC(5y)N/A
1SRPT.MI Yearly ROA, ROE, ROIC1SRPT.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • The Gross Margin of 1SRPT (69.33%) is comparable to the rest of the industry.
  • 1SRPT's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for 1SRPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.57%
GM growth 5Y-4.72%
1SRPT.MI Yearly Profit, Operating, Gross Margins1SRPT.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. 1SRPT.MI Health Analysis

2.1 Basic Checks

  • 1SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for 1SRPT has been increased compared to 1 year ago.
  • Compared to 5 years ago, 1SRPT has more shares outstanding
  • Compared to 1 year ago, 1SRPT has an improved debt to assets ratio.
1SRPT.MI Yearly Shares Outstanding1SRPT.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
1SRPT.MI Yearly Total Debt VS Total Assets1SRPT.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • Based on the Altman-Z score of -0.86, we must say that 1SRPT is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of 1SRPT (-0.86) is worse than 66.67% of its industry peers.
  • 1SRPT has a Debt/Equity ratio of 0.73. This is a neutral value indicating 1SRPT is somewhat dependend on debt financing.
  • 1SRPT has a Debt to Equity ratio (0.73) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF N/A
Altman-Z -0.86
ROIC/WACCN/A
WACC6.69%
1SRPT.MI Yearly LT Debt VS Equity VS FCF1SRPT.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 2.32 indicates that 1SRPT has no problem at all paying its short term obligations.
  • 1SRPT has a Current ratio (2.32) which is comparable to the rest of the industry.
  • A Quick Ratio of 1.48 indicates that 1SRPT should not have too much problems paying its short term obligations.
  • The Quick ratio of 1SRPT (1.48) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.32
Quick Ratio 1.48
1SRPT.MI Yearly Current Assets VS Current Liabilites1SRPT.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. 1SRPT.MI Growth Analysis

3.1 Past

  • The earnings per share for 1SRPT have decreased strongly by -391.67% in the last year.
  • The Revenue has grown by 15.58% in the past year. This is quite good.
  • Measured over the past years, 1SRPT shows a very strong growth in Revenue. The Revenue has been growing by 32.41% on average per year.
EPS 1Y (TTM)-391.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-362%
Revenue 1Y (TTM)15.58%
Revenue growth 3Y33.07%
Revenue growth 5Y32.41%
Sales Q2Q%-32.73%

3.2 Future

  • Based on estimates for the next years, 1SRPT will show a very strong growth in Earnings Per Share. The EPS will grow by 20.10% on average per year.
  • Based on estimates for the next years, 1SRPT will show a decrease in Revenue. The Revenue will decrease by -7.26% on average per year.
EPS Next Y145.42%
EPS Next 2Y52.38%
EPS Next 3Y31.54%
EPS Next 5Y20.1%
Revenue Next Year-19.12%
Revenue Next 2Y-18.8%
Revenue Next 3Y-12.48%
Revenue Next 5Y-7.26%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
1SRPT.MI Yearly Revenue VS Estimates1SRPT.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
1SRPT.MI Yearly EPS VS Estimates1SRPT.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

4

4. 1SRPT.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for 1SRPT. In the last year negative earnings were reported.
  • With a Price/Forward Earnings ratio of 5.64, the valuation of 1SRPT can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, 1SRPT is valued cheaper than 98.77% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of 1SRPT to the average of the S&P500 Index (22.70), we can say 1SRPT is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 5.64
1SRPT.MI Price Earnings VS Forward Price Earnings1SRPT.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
1SRPT.MI Per share data1SRPT.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • 1SRPT's earnings are expected to grow with 31.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.38%
EPS Next 3Y31.54%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. 1SRPT.MI Dividend Analysis

5.1 Amount

  • No dividends for 1SRPT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

1SRPT.MI Fundamentals: All Metrics, Ratios and Statistics

SAREPTA THERAPEUTICS INC

BIT:1SRPT (3/12/2026, 7:00:00 PM)

14.74

-4.1 (-21.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-04
Inst Owners89.94%
Inst Owner ChangeN/A
Ins Owners5.12%
Ins Owner ChangeN/A
Market Cap1.55B
Revenue(TTM)2.20B
Net Income(TTM)-713.41M
Analysts67.27
Price Target26.4 (79.1%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-57.12%
Min EPS beat(2)-213.05%
Max EPS beat(2)98.8%
EPS beat(4)2
Avg EPS beat(4)-85.92%
Min EPS beat(4)-376.26%
Max EPS beat(4)146.84%
EPS beat(8)5
Avg EPS beat(8)217.73%
EPS beat(12)8
Avg EPS beat(12)382.89%
EPS beat(16)10
Avg EPS beat(16)274.39%
Revenue beat(2)2
Avg Revenue beat(2)13.2%
Min Revenue beat(2)10.8%
Max Revenue beat(2)15.59%
Revenue beat(4)4
Avg Revenue beat(4)11.58%
Min Revenue beat(4)6.86%
Max Revenue beat(4)15.59%
Revenue beat(8)7
Avg Revenue beat(8)7.41%
Revenue beat(12)10
Avg Revenue beat(12)6.28%
Revenue beat(16)13
Avg Revenue beat(16)4.84%
PT rev (1m)2.4%
PT rev (3m)-3.07%
EPS NQ rev (1m)237.78%
EPS NQ rev (3m)157.78%
EPS NY rev (1m)8.56%
EPS NY rev (3m)24.63%
Revenue NQ rev (1m)26.85%
Revenue NQ rev (3m)20.33%
Revenue NY rev (1m)8.35%
Revenue NY rev (3m)8.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.64
P/S 0.81
P/FCF N/A
P/OCF N/A
P/B 1.57
P/tB 1.61
EV/EBITDA N/A
EPS(TTM)-5.76
EYN/A
EPS(NY)2.61
Fwd EY17.73%
FCF(TTM)-2.6
FCFYN/A
OCF(TTM)-1.69
OCFYN/A
SpS18.12
BVpS9.4
TBVpS9.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.3%
ROE -62.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.33%
FCFM N/A
ROA(3y)-10.59%
ROA(5y)-13.51%
ROE(3y)-36.51%
ROE(5y)-67.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.57%
GM growth 5Y-4.72%
F-Score3
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 246.73%
Cap/Sales 5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.32
Quick Ratio 1.48
Altman-Z -0.86
F-Score3
WACC6.69%
ROIC/WACCN/A
Cap/Depr(3y)277.68%
Cap/Depr(5y)204.92%
Cap/Sales(3y)6.58%
Cap/Sales(5y)5.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-391.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-362%
EPS Next Y145.42%
EPS Next 2Y52.38%
EPS Next 3Y31.54%
EPS Next 5Y20.1%
Revenue 1Y (TTM)15.58%
Revenue growth 3Y33.07%
Revenue growth 5Y32.41%
Sales Q2Q%-32.73%
Revenue Next Year-19.12%
Revenue Next 2Y-18.8%
Revenue Next 3Y-12.48%
Revenue Next 5Y-7.26%
EBIT growth 1Y-325.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year193.88%
EBIT Next 3Y31.21%
EBIT Next 5Y17.55%
FCF growth 1Y10.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.15%
OCF growth 3YN/A
OCF growth 5YN/A

SAREPTA THERAPEUTICS INC / 1SRPT.MI Fundamental Analysis FAQ

What is the fundamental rating for 1SRPT stock?

ChartMill assigns a fundamental rating of 3 / 10 to 1SRPT.MI.


Can you provide the valuation status for SAREPTA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 4 / 10 to SAREPTA THERAPEUTICS INC (1SRPT.MI). This can be considered as Fairly Valued.


How profitable is SAREPTA THERAPEUTICS INC (1SRPT.MI) stock?

SAREPTA THERAPEUTICS INC (1SRPT.MI) has a profitability rating of 1 / 10.


What is the financial health of SAREPTA THERAPEUTICS INC (1SRPT.MI) stock?

The financial health rating of SAREPTA THERAPEUTICS INC (1SRPT.MI) is 3 / 10.